UK markets close in 2 hours 25 minutes

Pharvaris N.V. (9EN.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
14.90+0.30 (+2.05%)
As of 11:35AM CEST. Market open.
Full screen
Previous close14.60
Open14.90
Bid0.00 x N/A
Ask0.00 x N/A
Day's range14.90 - 15.20
52-week range11.00 - 32.50
Volume100
Avg. volume5
Market cap505.292M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-4.86
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights

    RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks expanding to US, expected to report data in 2022 CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE attacks, and PHVS719 Phase 1 PK study expected to initiate in 2021Executing from a strong financial position with cash and cash equivalents of €224.3 million as of June 30, 2021 ZUG, Switzerland, July 30, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the de

  • Globe Newswire

    Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

    Multiple doses of PHA121 were well-tolerated and showed a favorable pharmacokinetic profile for prophylactic treatment of HAEZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the presentation of clinical data supporting the multi

  • Globe Newswire

    Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

    ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upco